EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Beyond Pain Scores: Molecular Biomarkers and the Emergence of Precision Pain Medicine

Ravi Shankar Sharma, Gaurav Sharma, Suyashi

Indian Journal of Pain · 2026-04 · 40 (2) · 51-56

DOI: 10.4103/ijpn.ijpn_77_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Pain, online erschienen am 30.06.2026. Verfasst von Ravi Shankar Sharma und 2 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Chronic pain is acknowledged as a multifactorial clinical condition rather than simply an indication of tissue damage. As per the recent literature, it is affecting nearly one in every five adults worldwide, and at the same time, it can contribute substantially to disability, psychological distress, and impaired quality of life with enhanced healthcare expenditure.[1] Despite the evolutionary advances in pain medicine, the assessment of pain is currently predominantly performed via subjective tools such as the Numerical Rating Scale, Visual Analog Scale, binary scales, and multidimensional scales such as the McGill Pain Questionnaire. Although these tools are effective in clinical scenarios, they are unable to capture the biological diversity underlying these chronic pain states. In clinics, chronic pain patients with apparently similar structural pathologies often present with widespread variation in pain intensities, disease trajectories, and responses to analgesic and co-analgesic therapies. Such widespread variations delineate the limitations of our conventional symptom-based pain syndrome classification and heavily support the need for mechanism- or molecular-based approaches for the management of these painful states. Over the last decade, multiple research studies have been provided that demonstrate chronic pain pathogenesis may involve dysregulation of the neuroimmune system, central sensitization, and unregulated neuroplasticity, along with impaired inflammatory signaling.[2] Prolonged and continuous activation of inflammatory activators such as cytokines, chemokines, neurotrophins, glial pathways, and genetic regulatory mechanisms further contributes to peripheral sensitization and, hence, amplification of central pain transmission.[3,4] Similar to advances in neurology, medical oncology, rheumatology, and radiotherapy, biomarkers are emerging as a crucial tool for objective pain phenotyping, prognostication, selection of treatment options, and therapeutic monitoring. Moreover, these molecular biomarkers may facilitate the shift from symptom-based management to individualized mechanism-based management in pain medicine, thereby establishing the groundwork for precision pain medicine. WHY DO BIOMARKERS MATTER IN CHRONIC PAIN? The greatest limitation of pain medicine is the absence of objective diagnostic tool. Perception of pain is influenced by multiple factors such as biological, emotional, cognitive, environmental, and genetic factors, which makes it inherently subjective and heterogeneous. Current management strategies often rely on conventional and empirical analgesic selection, leading to inconsistent outcomes, intolerable side effects, and unnecessary exposure to opioids.[5] Molecular markers or biomarkers have the potential to overcome several unmet needs in managing chronic pain syndrome by assisting in objective diagnosis of pain syndromes, mechanism-based phenotyping, disease prognostication, and prediction the response of the treatment, thereby monitoring the activity of the disease and identification of therapeutic targets for the development of individualized analgesics [Figure 1].[6]Figure 1: Molecular basis of chronic pain and precision pain medicine (figure created using ChatGPT [OpenAI] based on author-designed content and subsequently reviewed and edited by the author)Importantly, biological markers may assist in transition from diagnosis based on anatomy toward biological stratification. Future approaches may be able to identify the inflammatory and neuroimmune phenotypes or central sensitization based on molecular signatures of the disease, instead of labeling patients merely as having “low back pain” or “fibromyalgia.”[7] Similar to precision oncology or rheumatology, such an approach forms the basis of precision pain medicine, where treatment is tailored according to molecular and genetic profiles.[8] CLASSIFICATION OF MOLECULAR BIOMARKERS IN CHRONIC PAIN Various molecular biomarkers have been cited in literature, which may be further classified as inflammatory, neurotrophic, genetic, glial, and metabolomic categories [Table 1].Table 1: Major molecular biomarkers in chronic pain and their biological significanceInflammatory biomarkers Inflammatory mediators play an important role in sensitization of nociceptors and activation of the neuroimmune system. Elevated levels of inflammatory biomarkers such as cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), IL-1β, IL-8, and chemokines such as MCP-1/CCL2, have been persistently delineated in several chronic pain syndromes.[9] These biomarkers may contribute to peripheral sensitization with enhanced nociceptive transmission and glial activation, leading to the maintenance of chronic neuroinflammation. Neurotrophic and neural biomarkers CNS biomarkers, or biomarkers associated with nerve injury such as neurotrophins and neuropeptides, regulate the survival of neurons, synaptic plasticity, and central sensitization. Important biomarkers in this class include brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), substance P, calcitonin gene-related peptide (CGRP), and glutamate.[10] Of these, BDNF is of particular importance because it alters synaptic excitability and may contribute substantially to central sensitization. Genetic and epigenetic biomarkers Genetic variations and susceptibility in individuals may influence perception of pain, chronic pain vulnerability, and therapeutic response to analgesics. Important genes that may alter genetic susceptibility include COMT, SCN9A, OPRM1, and the TRPV1 gene.[11] Apart from these genes, epigenetic modifications such as deoxyribonucleic acid methylation and micro-ribonucleic acid regulation are also increasingly recognized in chronic pain chronification. Glial and neuroimmune biomarkers Glial cells, such as microglia and astrocytes, are now known to actively participate in the maintenance of chronic pain. Activated glial cells may release pro-inflammatory mediators, which can amplify central sensitization. Recent literature has also mentioned emerging glial biomarkers that include S100 proteins, glial fibrillary acidic protein, and microglial activation markers.[12] Metabolomic and proteomic biomarkers Recent literature has also demonstrated proteomic and metabolomic approaches that can identify molecular signatures associated with oxidative stress, mitochondrial dysfunction, extracellular matrix degradation, and lipid-mediated inflammation.[13] Utilizing this proteomics or “multi-omics” approach may thus ultimately help to generate reproducible molecular pain signatures. BIOMARKERS ASSOCIATED WITH DIFFERENT CHRONIC PAIN CONDITIONS As per recent literature, specific pain syndromes are associated with certain biomarkers, which are described as disease-specific markers [Table 2]. Chronic pain syndromes where disease-specific markers have been identified are as follows:Table 2: Disease-specific biomarker profiles in chronic pain conditionsNeuropathic pain Neuropathic pain occurs as a result of lesions or diseases affecting the central or peripheral nervous system and is characterized by spontaneous pain, tingling, numbness, hyperalgesia, and allodynia. As per recent literature, inflammatory cytokines such as TNF-α, IL-1β, and IL-6 and chemokines play a crucial role in peripheral and central sensitization. Elevated BDNF levels have been found to enhance synaptic hyperexcitability and persistent pain amplification. Furthermore, genetic polymorphisms involving sodium channel genes such as SCN9A further support the involvement of biomarkers in the causation of neuropathic pain.[14] Thus, these biomarkers may eventually help predict responses to analgesics and co-analgesic interventions such as gabapentinoids, antidepressants, sodium-channel blockers, and neuromodulation therapies. Osteoarthritis and degenerative pain Degenerative conditions such as osteoarthritis (OA) are increasingly recognized as inflammatory-metabolic disorders rather than purely mechanical degenerative conditions, and raised levels of IL-6, TNF-α, matrix metalloproteinases, cartilage oligomeric matrix protein, and adipokines such as leptin and resistin have been found to contribute to synovial inflammation and sensitization of nociceptors.[15] Alternatively, obesity-related adipose dysfunction may further enhance the chronic low-grade inflammation and OA pain progression. Thus, biomarker-guided phenotyping may assist in identifying inflammatory OA phenotypes that are potentially responsive to targeted biological therapies. Fibromyalgia and nociplastic pain As per recent research, fibromyalgia is considered nociplastic pain and is characterized by widespread pain, fatigue, sleep disturbances, and cognitive dysfunction without clear structural pathology. Further recent evidence strongly supports central sensitization and neuroimmune dysregulation in fibromyalgia. Elevated levels of biomarkers such as IL-8, substance P, BDNF, and S100 proteins have been reported in fibromyalgia patients; however, none of these biomarkers appear sufficient to characterize fibromyalgia. Thus, evaluation of composite biomarker signatures may better represent nociplastic pain states.[16] Chronic low back pain Chronic low back pain (CLBP) is widely recognized as one of the most common pain conditions presenting to the outpatient department (OPD) globally and specifically within India, and it involves inflammatory, neuropathic, degenerative, and nociplastic mechanisms. Raised levels of TNF-α, IL-6, IL-1β, CRP, and CGRP have already been demonstrated in patients suffering from CLBP. Furthermore, several studies have shown marked reductions in these biomarkers following exercise therapy, yoga, spinal manipulation, and multidisciplinary rehabilitation.[17] This further suggests that biomarker modulation may potentially serve as an objective treatment-monitoring tool. Cancer pain Pain associated with cancer can be multifactorial and often involves inflammatory, neuropathic, ischemic, and treatment-related mechanisms. The tumor microenvironment in a person affected with cancer releases IL-6, TNF-α, IL-1β, prostaglandins, endothelin-1, and NGF, and these mediators may contribute to sensitization of nociceptors, neuroinflammation, and bone pain. Thus, NGF has emerged as a crucial therapeutic target in cancer-related pain and bone metastasis pain.[18] Migraine and neurogenic pain Chronic headache conditions, specifically migraine, represent one of the earliest and successful examples of biomarker-guided precision pain therapeutics. Migraine pathogenesis includes CGRP-mediated trigeminovascular activation and neurogenic inflammation. The development of CGRP antagonists and monoclonal antibodies has transformed migraine therapy and validated the concept of targeted biomarker-based pain management.[19] BIOMARKERS AS THERAPEUTIC TARGETS IN CHRONIC PAIN The growing understanding of molecular pain pathways has led to the development of targeted therapies acting directly on biomarker pathways [Table 3]. These therapeutic targets include the following therapies:Table 3: Therapeutic agents acting on pain biomarkersAnti-nerve growth factor therapy NGFs play an important role in sensitization of nociceptors and pathological sprouting of nerves. Therapeutic agents such as monoclonal antibodies, including tanezumab and fasinumab, have demonstrated promising analgesic effects in OA and cancer pain.[20] However, due to safety concerns regarding rapidly progressive OA, it has limited its widespread clinical adoption. Cytokine-directed therapies These agents include TNF inhibitors such as infliximab, etanercept, and adalimumab, and they have shown benefits in inflammatory pain conditions. Similarly, IL-6 inhibitors such as tocilizumab are also being explored for chronic inflammatory and neuropathic pain states.[21] Calcitonin gene-related peptide-targeted therapies CGRP antagonists, including erenumab, fremanezumab, and galcanezumab, are some of the popular agents that are widely used in migraine management and represent an excellent example of precision pain medicine.[19] Glial modulation therapies Microglial activation can significantly contribute to central sensitization, thereby leading to a chronic painful state. Agents targeting these targets, such as minocycline and low-dose naltrexone, are currently being investigated as glial modulators in fibromyalgia and neuropathic pain.[22] Sodium channel targeting Neuropathic pain syndromes are frequently associated with sodium channel abnormalities, and blocking of these channels has been helpful since the past for the management of intractable neuropathic pain syndromes. Genetic insights involving SCN9A mutations have stimulated the development of selective NaV1.7 sodium-channel blockers for the management of neuropathic pain syndromes.[14] PRECISION PAIN MEDICINE: FUTURE PERSPECTIVES The future of chronic pain management may depend less on anatomical diagnosis but will depend more on the molecular pathways driving it. Precision pain medicine aims to integrate all the modalities, including molecular biomarkers, neuroimaging, quantitative sensory testing, genomics, metabolomics, and artificial intelligence (AI), thereby assisting in better management of chronic pain syndromes [Figure 2].[6,23] Such approaches may help to identify biologically meaningful pain endotypes and thereby facilitate personalized analgesic strategies. Potential future applications include predicting response to chronic pain interventions such as radiofrequency ablation, neuromodulation, pain biologic therapies, regenerative medicine, and opioid responsiveness. AI and machine learning may further enable the integration of complex biomarker datasets into clinically useful predictive algorithms.Figure 2: Multi-omics approach in precision pain medicine (figure created using ChatGPT [OpenAI] based on author-designed content and subsequently reviewed and edited by the author)Challenges and Limitations Despite recent advances, several limitations obstruct clinical translation of pain biomarkers into reality. First, most biomarkers remain associative rather than causative; for example, raised cytokines may reflect generalized inflammation rather than pain-specific mechanisms.[24] Second, chronic pain syndromes are biologically heterogeneous, and reproducibility across biomarker studies remains inconsistent due to variations in patient population, disease staging, laboratory techniques, and medication exposure.[16] Third, none of the single or universal biomarkers currently possess adequate sensitivity or specificity for routine clinical application.[25] Additionally, these assay costs remain high, longitudinal validation studies are limited, and standardized biomarker panels are lacking.[6] Thus, biomarker-guided pain medicine remains promising but still evolving. FUTURE RESEARCH DIRECTIONS Future biomarker research should target improving standardized assay methodologies, longitudinal biomarker monitoring, multi-omics integration, AI-driven phenotyping, and biomarker panels rather than isolated markers. Wearable biosensors capable of real-time inflammatory monitoring may eventually enable dynamic pain assessment. Importantly, there is a significant paucity of Indian biomarker datasets in chronic pain research. Furthermore, to develop population-specific precision pain models relevant to Indian patients, we urgently need large multicentric translational trials and biobanking initiatives. CONCLUSION Molecular biomarkers are reshaping the conceptual framework of chronic pain by linking clinical phenotypes with underlying biological or molecular mechanisms. Increasing evidence, including systemic reviews and meta-analyses, supports the role of inflammatory cytokines, neurotrophins, glial mediators, genetic polymorphisms, and metabolomic alterations in chronic pain pathophysiology. Although currently there is a lack of a universal biomarker, integrated biomarker signatures may help in facilitating objective pain phenotyping, individualized therapy, and targeted therapeutic development. Further, the integration of biomarkers with neuroimaging, genomics, AI, and multi-omics platforms has the potential to transform pain medicine from an empirical, symptom-based practice towards true precision pain medicine.

Zitieren

APA

Sharma, R. S., Sharma, G., & Suyashi (2026). Beyond Pain Scores: Molecular Biomarkers and the Emergence of Precision Pain Medicine. Indian Journal of Pain, 40(2), 51-56. https://doi.org/10.4103/ijpn.ijpn_77_26

Vancouver

Sharma RS, Sharma G, Suyashi. Beyond Pain Scores: Molecular Biomarkers and the Emergence of Precision Pain Medicine. Indian Journal of Pain. 2026;40(2):51-56. doi:10.4103/ijpn.ijpn_77_26

BibTeX
@article{Sharma2026,
  author = {Sharma, Ravi Shankar and Sharma, Gaurav and Suyashi},
  title = {Beyond Pain Scores: Molecular Biomarkers and the Emergence of Precision Pain Medicine},
  journal = {Indian Journal of Pain},
  year = {2026},
  volume = {40},
  number = {2},
  pages = {51--56},
  doi = {10.4103/ijpn.ijpn_77_26}
}
Kostenlos starten →